S&P 500 may face selling pressure as systematic funds reach full exposure
Investing.com -- Biovie Inc (NASDAQ:BIVI) stock jumped 7.3% following the company’s presentation of promising data for its Alzheimer’s drug bezisterim at a conference in Rome.
The clinical-stage biotech company revealed that bezisterim demonstrated significant biological age deceleration in Alzheimer’s disease patients compared to placebo in its Phase 3 study. After 30 weeks of treatment, patients receiving the drug experienced age deceleration of up to 4.24 years across various biological clocks measured.
The data was presented at the 2nd World Conference on Aging and Gerentology in Rome, Italy on July 14-15, 2025. The findings came from an analysis of 33 blood samples from the company’s Phase 3 NM101 study evaluating bezisterim in patients with mild-to-moderate probable Alzheimer’s Disease.
Beyond age deceleration effects, bezisterim appeared to modulate gene expression in the inflammatory cascade, resulting in reduced expression of inflammatory cytokines. The drug also showed potential beneficial modulation of genes associated with aging and Alzheimer’s Disease pathophysiology.
Patients treated with bezisterim experienced significant improvements in metabolic and inflammatory biomarkers compared to placebo, including reductions in fasting glucose (-8.5 mg/dL), cholesterol (-15 mg/dL), and MCP (-90.5 pg/mL).
Bezisterim is described as a stabilized version of Beta AET, a naturally occurring brain metabolite that decreases with age. Unlike its natural counterpart, bezisterim is metabolically stable, orally available, and able to cross the blood-brain barrier.
The company noted it is conducting ongoing studies to further explore these findings and considering whether bezisterim might help improve healthspan in normal aging.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.